OCEA Ocean Bio: Earnings per share for the last twelve months
The 12-month trailing earnings per share history demonstrates the financial background of Ocean Biomedical, Inc. (OCEA), which integrates ESG principles and strict bioethics into the development of immune drugs. Analysis shows that -0.34 determines the current value of this metric, while the holding company minimizes risks through the development of cancer and malaria therapies, anticipating future monetization of its patents via B2B licensing.
Analytical breakdowns and data insights for company Ocean Biomedical Inc (OCEA)
- current quotes and average value forecast:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital Ocean Biomedical, Inc.|OCEA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ocean Bio|OCEA - Company Cumulative Debt|Debts to Book Capitalization Ocean Biomedical, Inc.|OCEA - Company Long-Term Liabilities|Company Short-Term Debts Ocean Biomedical|Quick Ratio oceanbiomedical.com
- earnings and valuation multiples indicators:
OCEA - Net Profit|Expected Profit Ocean Biomedical, Inc.|OCEA - Price to Earnings Multiple|Projected Price to Earnings Ocean Biomedical|OCEA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Ocean Biomedical, Inc.|OCEA - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Ocean Biomedical|OCEA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months oceanbiomedical.com|OCEA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Ocean Biomedical, Inc.
- sales and revenue data:
Basic company analysis:Ocean Biomedical, Inc. (OCEA)
This indicator reflects the efficiency of profit generation accounting for equity dilution. This metric aggregates annual net income, allocating it per common share. For Ocean Biomedical, Inc. (OCEA), whose success depends on patents and venture capital infusions rather than GDP, this calculation reveals the actual monetization of its developments. By analyzing the trend of annual net income per share, an investor assesses the fundamental stability of the biotech firm.
Competitor analysis
ARGX - Earnings per share for the last twelve months|biontech.de (BNTX) - Net earnings per share for the last 12 months|Abivax Pharma (ABVX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ADMA Biologics Inc|Net earnings per share for the last 12 months PTGX|Net earnings per share (EPS TTM) Immunovant Therapeutics|Earnings per share for the last twelve months Kiniksa Pharmaceuticals (KNSA)|grifols.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ADPT (Adaptive Biotechnologies Corporation)|Celldex Therapeutics Inc (CLDX) - Net earnings per one share for the last twelve months|AUPH - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months BioCryst Corp|VERA: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months dianthustx.com|PHVS (Pharvaris) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months AbCellera Biologics Inc ABCL|Net earnings per share (EPS TTM) TRML|Net earnings per share (EPS TTM) Precigen Corp (PGEN)|Earnings per share for the last twelve months Pharming Group N.V. PHAR|NKTR: Earnings per share for the last 12 months|UPB: Net earnings per share for the last 12 months|Earnings per share for the trailing year ZBIO (Zenas Bio)|IMNM: Net earnings per share (EPS TTM)|GOSS (Gossamer Bio Corp.) - Earnings per share for the last twelve months|KALV (KalVista Pharmaceuticals) - Net earnings per share (EPS TTM)|septerna.com (SEPN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pieris Pharmaceuticals, Inc. (PVLA)|SVRA - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Rigel Pharmaceuticals Inc RIGL|ANAB - Net earnings per share for the last 12 months|Astria Therapeutics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months engene.com|RAPT: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months JBIO|ACRS (Aclaris) - Net earnings per share (EPS TTM)|Kyverna Therapeutics, Inc (KYTX) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) TLSA|Net earnings per share for the last 12 months cabalettabio.com CABA|Net earnings per share (EPS TTM) VTYX (Ventyx Biosciences, Inc.)|Net earnings per share (EPS TTM) Theratechnologies, Inc. THTX|AVTX - Earnings per share for the last twelve months|ELDN: Earnings per share for the last twelve months|AGEN (Agenus) - Net earnings per share for the last 12 months|climbbio.com - Earnings per share for the trailing year|ZURA (Zura Bio Limited) - Net earnings per share (EPS TTM)|aTyr Pharma Inc (ATYR) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Adagene (ADAG)|ikenaoncology.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) STTK (Shattuck Labs)|EQ - Net earnings per share for the last 12 months|CNTB: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Immunic, Inc. IMUX|atarabio.com (ATRA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months InflaRx (IFRX)|XFOR (X4 Pharmaceuticals) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Adicet (ACET)|Net earnings per share (EPS TTM) CELU|INMB - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BRNS (Barinthus Bio)|Net earnings per share (EPS TTM) Kezar Life Sciences Inc KZR|SABS - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AKTX|ENLV: Net earnings per share (EPS TTM)|Q32 Bio - Earnings per share for the trailing year|GOVX (GeoVax Labs Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Edesa Biotech Corp|Earnings per share for the last twelve months iBio, Inc. (IBIO)|CARM (carismatx.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months XTL Biopharmaceuticals Ltd. XTLB|BOLT - Net earnings per share for the last 12 months|HCW Biologics Inc - Net earnings per share (EPS TTM)|APVO - Net earnings per share (EPS TTM)|AIM (AIM ImmunoTech) - Net earnings per share for the last 12 months|Aditxt, Inc. - Earnings per share for the trailing year|GRI (GRI Bio) - Net earnings per share (EPS TTM)|XORTX Therapeutics Inc (XRTX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months ReShape Lifesciences (HIND)|Net earnings per share for the last 12 months Revelation Biosciences Corp REVB|Earnings per share for the last twelve months Indaptus Therapeutics INDP|SCNI - Net earnings per share for the last 12 months|CALI: Net earnings per share for the last 12 months|AFMD - Net earnings per share (EPS TTM)|allakos.com (ALLK) - Earnings per share for the last twelve months|Earnings per share for the last 12 months HOOK|IGMS (IGM Biosciences Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months iteostherapeutics.com ITOS|Earnings per share for the last twelve months TC BioPharm (TCBP)|THRD - Net earnings per one share for the last twelve months
